FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma By Ogkologos - January 31, 2025 443 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study CK-301-101 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients... February 24, 2026 Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected... September 30, 2025 Transforming Cancer Clinical Trials for Better, Faster Results April 14, 2023 The Taylor Family Foundation gives £2.1m to support head and neck... December 12, 2022 Load more HOT NEWS Patients less likely to rate cancer care as ‘very good’ during... Nature’s Bounty: Revitalizing the Discovery of New Cancer Drugs from Natural... Cancer Prevention Message Is Key for HPV Vaccination Discussions with Parents A College Senior vs. A Global Pandemic
